Barbara MacGregor-Cortelli
Overview
Explore the profile of Barbara MacGregor-Cortelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
405
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
OConnor O, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Hamlin P, et al.
J Natl Compr Canc Netw
. 2009 Oct;
2 Suppl 4:S21-2.
PMID: 19791425
Dr. O'Connor delivered the following material as a poster at the 2003 American Society of Hematology meeting highlighting results from his work with bortezomib in the treatment of non-Hodgkin's and...
2.
OConnor O, Horwitz S, Hamlin P, Portlock C, Moskowitz C, Sarasohn D, et al.
J Clin Oncol
. 2009 Aug;
27(26):4357-64.
PMID: 19652067
Purpose: To determine the maximum-tolerated dose (MTD) and efficacy of pralatrexate in patients with lymphoma. Patients And Methods: Pralatrexate, initially given at a dose of 135 mg/m(2) on an every-other-week...
3.
Gumbs A, Zain J, Neylon E, MacGregor-Cortelli B, Patterson M, OConnor O
Ann Surg Oncol
. 2009 May;
16(7):2014-7.
PMID: 19408055
Objective: T-cell lymphomas (TCLs) classically have a poorer response to therapy when compared with B-cell lymphomas and account for only 10-15% of all lymphoid malignancies. Hepatosplenic TCLs are a rare...
4.
Marneros A, Grossman M, Silvers D, Husain S, Nuovo G, MacGregor-Cortelli B, et al.
Blood
. 2009 Apr;
113(25):6338-41.
PMID: 19389878
Pralatrexate is a novel antifolate, which shows increased antitumor activity in human tumor xenograft studies in mice compared with methotrexate. We investigated the effects of pralatrexate in a patient with...
5.
OConnor O, Hamlin P, Portlock C, Moskowitz C, Noy A, Straus D, et al.
Br J Haematol
. 2007 Oct;
139(3):425-8.
PMID: 17910632
T-cell lymphomas (TCLs) are characterised by poor responses to therapy with brief durations of remissions. An early phase study of pralatrexate has demonstrated dramatic activity in patients with relapsed/refractory disease....
6.
Gerecitano J, Goy A, Wright J, MacGregor-Cortelli B, Neylon E, Gonen M, et al.
Br J Haematol
. 2006 Aug;
134(4):391-8.
PMID: 16882131
Bortezomib is the first proteasome inhibitor to be approved for use in haematological malignancies. Although a rash has been described as a common adverse event associated with the drug, it...
7.
OConnor O, Heaney M, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, et al.
J Clin Oncol
. 2005 Dec;
24(1):166-73.
PMID: 16330674
Purpose: To document the toxicity and activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with pretreated hematologic malignancies. Patients And Methods: Two formulations of SAHA (intravenous...
8.
OConnor O, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, et al.
J Clin Oncol
. 2004 Dec;
23(4):676-84.
PMID: 15613699
Purpose: To determine the antitumor activity of the novel proteasome inhibitor bortezomib in patients with indolent and mantle-cell lymphoma (MCL). Patients And Methods: Patients with indolent and MCL were eligible....